ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 41 for:    synovial | "Dermatofibroma"

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00474994
Recruitment Status : Completed
First Posted : May 17, 2007
Results First Posted : January 20, 2016
Last Update Posted : January 20, 2016
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Adult Malignant Fibrous Histiocytoma of Bone
Desmoid Tumor
Endometrial Cancer
Ovarian Cancer
Sarcoma
Small Intestine Cancer
Intervention: Drug: sunitinib malate

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas

Participant Flow:   Overall Study
    Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
STARTED   53 
COMPLETED   48 
NOT COMPLETED   5 
Patient Not treated                1 
Patient evaluable for toxicity only                3 
Patient found to be ineligible                1 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas

Baseline Measures
   Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas 
Overall Participants Analyzed 
[Units: Participants]
 53 
Age 
[Units: Participants]
 
<=18 years   1 
Between 18 and 65 years   45 
>=65 years   7 
Gender 
[Units: Participants]
 
Female   28 
Male   25 


  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Mary Keohan
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4160
e-mail: KeohanM@mskcc.org


Publications of Results:

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00474994     History of Changes
Other Study ID Numbers: 07-054
P30CA008748 ( U.S. NIH Grant/Contract )
MSKCC-07054
PFIZER-MSKCC-07054
First Submitted: May 16, 2007
First Posted: May 17, 2007
Results First Submitted: December 15, 2015
Results First Posted: January 20, 2016
Last Update Posted: January 20, 2016